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Variable Preprocedure Postprocedure*
6-Month
Follow-up*
N 126 126 113
Lesion length, mm 11.203.77 - -
Reference diameter, mm 3.060.31 3.090.26 3.010.29
MLD, mm 0.920.40 2.670.28 2.450.44
% DS 69.912.3 13.57.8 18.313.6
Acute gain, mm - 1.730.45 -
% acute recoil, mm - 6.66.2 -
Late lumen loss, mm - - 0.210.34
*In-scaffold
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Short- and intermediate- term clinical outcomes after implantation of
everolimus-eluting bioresorbable scaffold in complex lesions : a prospective
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Background: Bioresorbable scaffold is a novel approach that provides transient
vessel support with drug delivery capability without the long-term limitations of
metallic drug-eluting stents. The everolimus-eluting bioresorbable scaffold
(ABSORB; Abbott vascular, CA, USA) has been shown to be effective in the context
of ﬁrst-in-man trials including simple lesion(s). However, the effect of ABSORB
implantation in more complex patients cannot be directly extrapolated from these
ﬁndings. We sought to evaluate the impact of this novel technology on the short- and
intermediate- term clinical outcomes in a real-life population with complex lesions.
Methods: Since September 1st 2013, our institution commenced the use of
ABSORB scaffold in patients with complex lesions including a long lesion
(>32mm in length), a calciﬁed lesion, a bifurcation lesion and a large vessel with
up to 4mm in diameter. Patients presenting with stable angina, unstable angina and
non-ST elevation myocardial infarction were included. In total 300 patients pre-
senting with de novo complex lesions will be treated exclusively with ABSORB
scaffolds.
Results: Up to May 1, 2013, 137 patients were included in the study. In total 248
scaffolds were implanted, with a procedural success rate of 95%, in the lesions
including 40 bifurcations and 11 chronic total occlusions. In 52 patients (53 lesions),
more than one scaffold was implanted with overlap. An interim analysis of the pop-
ulation at one month revealed no MACE event except for one myocardial infarction.
The enrolment is ongoing while the updated one-month and 6-month data on the
occurrence of death, MI, repeat revascularization and scaffold thrombosis are
currently being collected and will be presented at the time of the meeting. Survival
information will be obtained from municipal civil registries.
Conclusions: The short-term and intermediate-term clinical safety and efﬁcacy of the
ABSORB scaffold in complex lesions will be presented at the meeting.
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Background: The ABSORBTM bioresorbable vascular scaffold (BVS) (Abbott
Vascular, Santa Clara, CA, USA) is a resorbable polymeric scaffold that provides
temporary scaffolding and everolimus drug delivery. The resorption of the BVS
potentially overcomes the limitations of metallic stents. There is limited data on its use
in daily clinical practice, especially in acute coronary syndrome (ACS) patients and
complex lesions. We assessed the safety and performance of ABSORB BVS
implantation in a selected patient cohort comparable with "real world" situation.
Methods: All patients who had undergone percutaneous coronary intervention (PCI)
with ABSORB BVS implantation in our centre between August 2012 and June 2013
were included in this registry. Clinical outcome were deﬁned as cardiac death,
myocardial infarction (MI), target vessel revascularization (TVR), target lesion rav-
ascularization (TLR), scaffold thrombosis (ST), and major adverse cardiac event
(MACE; composite of cardiac death, MI and TVR). In addition, Quanitative Coronary
Analysis including angiographic success rate will be performed and available at TCT.
Results: A total of 117 patients (136 lesions) were treated with an ABSORB BVS.
The indication for PCI was stable angina in 53 patients (45%), non ST-segment
elevation acute coronary syndrome (NSTE-ACS) in 38 patients (33%), and ST-
segment elevation myocardial infarction (STEMI), in the setting of primary PCI, in 20
patients (17%). In total 64% of the 136 lesions had type B2 or C ACC/AHA classi-
ﬁcation, including 9 chronic total occlusions, 2 left main, 4 ostial, 3 long (>50 mm)
and 8 complex bifurcation lesions treated with Tryton bifurcation stent and BVS. At
least 1 month follow-up was available in 94 patients (median follow up 54 days; Q1-
Q3: 40-67). MACE occurred in 4 patients (4.2%). Two patients experienced MI due to
subacute scaffold thrombosis and two patients needed target vessel revascularization,
including one target lesion, due to recurrent angina pectoris.
Conclusions: In a patient population reﬂecting daily clinical practice, including high-
risk lesions and high-risk patients, the ABSORB BVS had good short term results.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-431
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Background: By design, drug-eluting bioresorbable scaffolds have been developed as
an alternative to metallic stents in order to provide temporary vascular scaffolding,
prevent vessel recoil and inhibit late clinical events due to excessive neointimal
hyperplasia formation including restenosis and lesion revascularization. The DES-
olve bioresorbable scaffold (Elixir Medical Co., Sunnyvale, CA) is a novel device
combining a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and a potent anti-proliferative sirolimus metabolite Novolimus, with a drug
dose of 5 mcg per mm of scaffold length. Our objective was to report serial QCA results
from the prospective, non-randomized, single-arm multicentre DESolve Nx trial.
Methods: A total of 126 patients/lesions were enrolled in 13 sites in Europe, New
Zealand and Brazil. Lesion criteria were single de novo lesion <14 mm in length,
located in native coronary vessels 2.75-3.50 mm in diameter, with stenosis between
50-90% and TIMI ﬂow 2. The study device was available in 3.00, 3.25 and 3.50 mm
in diameter and 14 and 18 mm in length. All patients were assigned to angiographic
follow-up at 6 months. Quantitative coronary angiography (QCA) analysis was
performed at an independent angiographic core laboratory.
Results: Overall, mean age was 62 years and 21% had diabetes. Target lesions were
evenly distributed in LAD, LCx and RCA, and most lesions were classiﬁed as type B
(71%) according to the ACC/AHA classiﬁcation. During procedure, the study device was
successfully implanted in 122/126 cases (97%). Serial QCA results are shown in the Table.Conclusions: Angiographic results of the novel DESolve bioresorbable scaffold
showed promising results in de novo coronary artery lesions including relatively
low in-scaffold late lumen loss, a surrogate of neointimal hyperplasia, at 6-month
follow-up.
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Background: The use of bioresorbable vascular scaffolds (BVS) has largely been
restricted to simple lesions with a relatively small number of patients treated with
complex lesions. The aim of this study was to evaluate the device success and short-
term clinical outcomes of BVS in 'real world' patients including those with complex
coronary lesions.
Methods: All consecutive patients treated with BVS between May 2012 and June
2013 at 2 centers were included in this analysis.
Results: A total of 123 lesions in 82 patients (87.8% male, mean age 64.6 years) were
treated with BVS. Complex lesions were distributed as follows: long lesion >20mm
(n¼83), bifurcation lesions (n¼49), calciﬁed lesions (n¼42), chronic total occlusions
(n¼9) and in-stent restenoses (n¼7), one feature could be present inmore than one lesion.
Intracoronary vascular ultrasound and optical computed tomographywere used in 85.4%
and 20.3% of cases, respectively. Pre-dilation was performed in 98.4%, while post-
dilation (mean 21.5 atmosphere) was utilized in all cases. Rotablation or scoring balloon
was used in 22.0%. Device success was achieved in 99.2%. At median follow-up of 147acts/POSTER/Bioresorbable Vascular Scaffolds B133
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Sdays, there were no death, follow-up myocardial infarction or stent thrombosis. There
was however 1 case of target vessel revascularization not related to BVS.
Conclusions: These preliminary results suggest that complex lesions can possibly be
successfully treated with BVS. Intravascular ultrasound guidance and meticulous
technique may be important to optimize clinical outcomes.Circulatory Support, Heart Failure, and HOCM
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device support (TandemHeart): 6 years’ experience and outcomes
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Background: We have used the TandemHeart  (Cardiac Assist, Pittsburgh, PA)
percutaneous left ventricular assist device during percutaneous coronary intervention
(PCI) in patients for whom conventional PCI and aorto-coronary bypass would pose
substantial risk due to comorbidities and/or clinical presentation. We present a retro-
spective series of patients and report clinical outcomes with a 6 year follow up
Methods: We retrospectively analyzed data from 626 consecutive PCIs at the Texas
Heart Institute from 2005 to 2011. Among these, we identiﬁed 74 cases performed
with TandemHeart support. Cases were classiﬁed as elective, urgent, emergent, or
emergent salvage according to STS deﬁnitions. To standardize intervention's
complexity, we calculated each patient's SYNTAX score. Ejection fraction prior to the
procedure (EF), left mean atrial pressure prior to PCI (LAP), mean cardiac output
provided by mechanical support (mCO) and length of hemodynamic support provided
for successful weaning (LCS) were recorded. Incidences of 30-day mortality, pro-
longed hospital stay (i.e. hospitalization greater than 14 days), stroke, prolonged
ventilation (i.e. > 24 hours), post-procedural acute kidney injury (i.e. increase of
greater than 0.5 mg/dl in creatinine).
Results: Mortality at 30 days for the elective, urgent, emergent, and emergent salvage
subgroups was 6%, 12%, 22%, and 38%. Anatomic complexity(SYNTAX score),
hemodynamic instability(LAP)and morbidity were collected for each group. In the
elective subgroup LCS was 10.1 days and all patients in this group were successfully
weaned frommechanical support. In the urgent subgroup LCSwas 3.92.6 days and all
patients were successfully weaned from mechanical support. In the emergent subgroup
LCS was 3.92.6 days, and 84% (16/19) patients were successfully weaned from
mechanical support. In the rescue subgroup 67% of the patients (14/22) cardiopul-
monary resuscitation (CPR) was in progress or had recently performed prior to the
procedure, LCS was 6.94.5 days and 54%(12/22) patients were successfully weaned.
Conclusions: TandemHeart-assisted PCI is a valid option for revascularization in
profound cardiogenic shock and extreme-risk elective revascularization.
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Background: Percutaneous transluminal septal ablation (PTSMA) is an alternative
treatment to surgery in patients with hypertrophic obstructive cardiomyopathy
(HOCM) with advanced symptoms despite optimal medical treatment, specially under
high surgical risk. However, due to the relatively new introduction of the technique the
very long term results of PTSMA (>10 years) are unknown.
Methods: We have included in the present study consecutive patients with HOCM
treated with PTSMA in 5 centers between 1998 and 2003. We have analyzed clinical,
hemodymanic and echocardiographic data at baseline and follow up.
Results: A total of 45 patients were included, 31 (69%) women and mean age 62.4 14
years. Among those 39 (86.6%) were in NYHA class III or IV. The septum thickness was
21.83.5 mm, maximum basal gradient in echo 7739 mmHg and mitral regurgitationB134 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jwas at least moderate in 22 (48.8%). In hospitalization 3 pts required permanent pace-
maker implantation and 1 pt had ventricular perforation (by pacing lead) undergoing
surgery. After a median follow up of 12.3 years (11-13.5), 9 pts died and among these 2
pts (4.4%) suffered cardiac death (heart failure and post-transplantation), 2 pts under-
went ICD implantation (the case with perforation and surgery due to subsequent
ventricular tachycardia, and other for primary prevention), 2 underwent cardiac surgery
(endocarditis and severe mitral regurgitation). In the last clinical review NYHA class
was I-II in 39 (86.6%), (p<0.0001), the maximum basal gradient was 1623 mmHg
(p<0.0001) and mitral regurgitation was absent or mild in 34 (75.5%) (p < 0.03).
Conclusions: The results of this study suggest safety and efﬁcacy for PTSMA at
a very long term follow up, over 10 years. A sustained reduction in gradients, mitral
regurgitation and functional class is observed. This treatment was not associated with
signiﬁcant incidence of sudden death or ventricular arrhythmias.
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Background: ASA is an established treatment for HOCM. Up to 30% have an
unsatisfactory outcome from intended treatment.
Methods: CT images are used to highlight the SAM-septal contact point. Vascular
supply to this area is identiﬁed, the course and origin of these vessels are described.
The target septal is labeled and a 3D angiogram created to deﬁne optimal angiographic
angles. All major epicardial arteries are surveyed to identify any further target vessels
and exclude those with an inappropriate distribution.
Results: 16 patients have undergone CT angiography prior to ASA. The approach to
ASA was changed in 9. CT can identify septal arteries that bifurcate to supply both the
left and right ventricular septum. Contrast injection into the ostium of such arteries
localises to the RV due to the pressure differential between coronary ﬂow to RV and
LV. On balloon occlusion of the LV sub-branch the contrast localises to the target area.
CT can reliably determine the sub-branch that supplies the target area. This has occurred
in 6/16 patients. 3 patients had epicardial artery source other than LAD (circumﬂex,
diagonal, obtuse marginal). 12 patients have received alcohol and have >1 month
review. 11/12 have improved dyspnoea (one has progressive pulmonary ﬁbrosis).
LVOT gradients have decreased by >50% from baseline to a ﬁnal level of <50mmHg
in all. Peak VO2 is improved in all 6 who have undergone 6-month testing.
Conclusions: CT has the ability to describe intricate details of septal arterial anatomy.
Our approach to ASA is changing and contrast localisation is more accurate. Initial
results are very encouraging.TCT Abstracts/POSTER/Circulatory Support, Heart Failure, and HOCM
